Mercola | 1 July 2024
- A preprint study led by Dr. Peter McCullough suggests using siRNA and RIBOTACs to target and degrade residual mRNA from COVID-19 vaccines, potentially mitigating long-term health risks associated with persistent spike protein production
- COVID-19 mRNA vaccines have shown wider distribution in the body than initially claimed, raising concerns about unintended effects and the need for an “off switch” to stop ongoing spike protein production
- The study proposes using siRNA and RIBOTACs as potential methods to bind to and degrade vaccine mRNA in cells, offering a targeted approach to prevent adverse events from mRNA-based therapies
- “Long vax” symptoms, similar to long COVID, have been reported following vaccination, including fatigue, brain fog, numbness, and cardiovascular issues, highlighting the need for effective treatments for those affected
- Another study led by McCullough found a significant increase in cerebral thromboembolism risk associated with COVID-19 vaccines compared to other vaccines, leading to calls for a moratorium on their use
Breakthrough Study Uncovers 'Off Switch' for COVID mRNA Shots
Source: https://tinyurl.com/28ad8a9c